Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Many CD8+ T cells in the melanoma microenvironment are becoming progressively dysfunctional yet remain highly proliferative, according to researchers.
Medicare coverage has been announced for Adaptive Biotechnologies’ clonoSEQ® next-generation sequencing assay for the detection of minimal residual disease (MRD) after treatment for multiple myeloma or B-cell acute lymphoblastic leukemia (ALL) — a key step toward its use for patient care in cancer clinics in the United States.1,2The FDA announced regulatory approval for the assay…
“People have shown that the variant-identification quality of WGS is superior to WES,” said Dr Gerstein.
Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field.
Inhibition of ER translocation prevented both ERK reactivation and autophagy, suggesting a potential strategy for improving BRAF and MEK inhibition therapy outcomes.
Results from the phase 3 Myeloma XI trial bolster earlier evidence that maintenance therapy with lenalidomide is associated with improved PFS for some patients with multiple myeloma.
The combination of trametinib and palbociclib induced attack by NK cells — but not killing — of xenograft lung tumors in lab animals.
Overall, patient survival was not associated with surgical technique.
Epigenetic aberrations, as opposed to DNA mutations themselves, might play a more important role in the progression of many malignancies.
